Apr 28, 2026 | Erasca Crashes 48% on Patient Death; Lilly's $2.3B Ajax Deal episode artwork

EPISODE · Apr 29, 2026 · 10 MIN

Apr 28, 2026 | Erasca Crashes 48% on Patient Death; Lilly's $2.3B Ajax Deal

from The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus · host BZ Group

Erasca loses half its market cap after a Phase 1 death —while AbbVie bets $1.45B on the same RAS target. Lilly acquires Ajax for $2.3B in its 5th deal of 2026; FDA alleges data manipulation behind Amgen's Tavneos; Boehringer survodutide hits 16.6% weight loss in Phase 3.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Erasca, ERAS-0015, pan-RAS, KRAS, AbbVie, Kestrel Therapeutics, Eli Lilly, Ajax Therapeutics, JAKinhibitor, myelofibrosis, Amgen, Tavneos, ChemoCentryx, data manipulation, Intellia Therapeutics, CRISPR, gene editing, BridgeBio, Vyndamax, Pfizer, Boehringer Ingelheim, survodutide, obesity, AstraZeneca, Breztri, asthma,Incyte, vitiligo, Oruka, psoriasis, Veradermics, Sanofi, tolebrutinib, Lilly

Erasca loses half its market cap after a Phase 1 death —while AbbVie bets $1.45B on the same RAS target. Lilly acquires Ajax for $2.3B in its 5th deal of 2026; FDA alleges data manipulation behind Amgen's Tavneos; Boehringer survodutide hits 16.6% weight loss in Phase 3.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Erasca, ERAS-0015, pan-RAS, KRAS, AbbVie, Kestrel Therapeutics, Eli Lilly, Ajax Therapeutics, JAKinhibitor, myelofibrosis, Amgen, Tavneos, ChemoCentryx, data manipulation, Intellia Therapeutics, CRISPR, gene editing, BridgeBio, Vyndamax, Pfizer, Boehringer Ingelheim, survodutide, obesity, AstraZeneca, Breztri, asthma,Incyte, vitiligo, Oruka, psoriasis, Veradermics, Sanofi, tolebrutinib, Lilly

NOW PLAYING

Apr 28, 2026 | Erasca Crashes 48% on Patient Death; Lilly's $2.3B Ajax Deal

0:00 10:07

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus?

This episode is 10 minutes long.

When was this The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus episode published?

This episode was published on April 29, 2026.

What is this episode about?

Erasca loses half its market cap after a Phase 1 death —while AbbVie bets $1.45B on the same RAS target. Lilly acquires Ajax for $2.3B in its 5th deal of 2026; FDA alleges data manipulation behind Amgen's Tavneos; Boehringer survodutide hits 16.6%...

Can I download this The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!